Page 220 - Haematologica Vol. 109 - July 2024

ARTICLE - Carfilzomib, thalidomide and dexamethasone (KTd) in RRMM S. Ninkovic et al. AB
CD
Figure 2. Progression-free survival and overall survival. (A, B) Progression-free survival is displayed for the entire cohort (A) and separated by ethnicity (B). (C, D) Overall survival is displayed for the entire cohort (C) and separated by ethnicity (D). mPFS: me- dian progression-free survival; mOS: median overall survival; 95% CI: 95% confidence interval; NR: not reached.
Table 2. Response by ethnicity.
Characteristic
Not Asian N=46
Asian N=44
P
Response by ethnicity ORR, N (%)
≥ VGPR, N (%)
≥ CR, N (%)
41 (89) 36 (78) 18 (39)
38 (86) 30 (68) 11 (25)
0.69 0.28 0.15
Progression-free survival Median (95% CI) in months 2-year PFS, % (95% CI)
20.0 (13.2-26.0) 59.8 (45.5-74.5)
22.5 (14.3-26.2) 50.4 (35.6-67.4)
0.18
Overall survival
Median (95% CI) in months 2-year OS, % (95% CI)
NR (27.7-NR) 70.9 (55.2-82.0)
46.1 (33.6-NR) 76.5 (59.6-87.1)
0.61
ORR: overall response rate; VGPR: very good partial response; CR: complete response; PFS: progression-free survival; 95% CI: 95% confidence interval; OS: overall survival; NR: not reached.
Haematologica | 109 July 2024
2234